Site icon Medical Market Research Blog | A Blog about Healthcare Survey

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) by the FDA

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) by the FDA

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is not breast cancer but a rare type of T-cell lymphoma that usually presents as a fluid swelling around the breast implants.

This is a very rare non-Hodgkin’s type of lymphoma and was first studied in 2011. The main treatment is the removal of implants along with scar tissue formed around it.  Occasionally, some patients require chemotherapy or radiation. [1]

As of February 1, 2017, the FDA has received a total of 359 medical device reports of BIA-ALCL including nine deaths. Of these, 203 were textured implants and 28 were smooth implants; 186 implants were filled with silicone gel and 126 were filled with saline.

Presently, the US FDA has released safety information regarding the current understanding of the incidence and prevalence of BIA-ALCL. This has been released corresponding to the World Health Organization designation of BIA-ALCL as a rare type of T-cell lymphoma, which occurs after wearing breast implants.[1]

Highlights of March 2017 FDA Update

Certain information highlighted for patients, especially for women with breast implants.

Exact determination of the number of cases remains difficult due to a lack of global sales data and worldwide reporting. However, receiving newer cases since 2011 and after finding the association between cancer and implants, FDA continues to collect and evaluate BIA-ALCL in women with breast implants.

Advice For Healthcare Providers


Credit: Dr. Rachita on behalf of Borderless Access

Copyright © 2017 BorderlessAccess



Breast Implants: Update – Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Spread the love
Exit mobile version